November 1, 2018
Denali, Sanofi together developing RIPK1 inhibitors for treating neurological and inflammatory diseases
Denali Therapeutics will work with Sanofi on its multiple RIPK1 inhibitor molecules that could treat a range of neurological and systemic inflammatory diseases.